SCHEMBL29640332

SCHEMBL29640332

CCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O)[C@@H](C)CC

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC6A5 Q9Y345 2/20 0.44
▸ ITGB3 P05106 4/20 0.43
▸ ITGA2B P08514 4/20 0.43
▸ FAAH O00519 4/20 0.40
▸ NOD1 Q9Y239 3/20 0.40
▸ ELANE P08246 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ ASAH1 Q13510 1/20 0.36
▸ ACER2 Q5QJU3 1/20 0.36
▸ PSMB5 P28074 1/20 0.36
▸ MME P08473 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ CPA1 P15085 1/20 0.36
▸ ACE2 Q9BYF1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29640354 1.00 SLC6A5 (0.44) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL30496953 1.00 SLC6A5 (0.44) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL30496934 1.00 SLC6A5 (0.44) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL17206101 0.93 SLC6A5 (0.47) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL17206100 0.93 SLC6A5 (0.47) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL30496960 0.92 SLC6A5 (0.46) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL29640338 0.92 SLC6A5 (0.46) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL30496952 0.92 SLC6A5 (0.46) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL30496947 0.92 SLC6A5 (0.46) SLC6A5ITGB3ITGA2BFAAHNOD1
SCHEMBL29809737 0.88 PSMB5 (0.42) SLC6A5ITGB3ITGA2BFAAHNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116979-A1 METHOD FOR PRODUCING LIPIDIC PEPTIDE NISSAN CHEMICAL CORPORATION (JP) 2024-04-11 — — US disclosed
US-20240067675-A1 METHOD FOR PRODUCING LIPID PEPTIDE NISSAN CHEMICAL CORPORATION (JP) 2024-02-29 — — US disclosed
EP-4265629-A1 METHOD FOR PRODUCING LIPID PEPTIDE Nissan Chemical Corporation (JP) 2023-10-25 — — EP disclosed
CN-116648455-A Method for preparing lipid peptide 日产化学株式会社 2023-08-25 — — CN disclosed
CN-116615435-A Method for preparing lipid peptide 日产化学株式会社 2023-08-18 — — CN disclosed
WO-2022138953-A1 METHOD FOR PRODUCING LIPID PEPTIDE 日産化学株式会社 2022-06-30 — — WO disclosed
WO-2022138957-A1 METHOD FOR PRODUCING LIPIDIC PEPTIDE 日産化学株式会社 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067675-A1 METHOD FOR PRODUCING LIPID PEPTIDE VIP, NGLY1, NPPA SLC6A5 1803/4885ITGB3 1694/4885ITGA2B 3002/4885
US-20240116979-A1 METHOD FOR PRODUCING LIPIDIC PEPTIDE NPPA, VIP, NGLY1 SLC6A5 1172/4885ITGB3 4464/4885ITGA2B 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback